EDITOR: | August 29th, 2017 | 1 Comment

Scythian CEO on the potential impact of cannabinoid drugs on traumatic brain injuries

| August 29, 2017 | 1 Comment
image_pdfimage_print

Jonathan Gilbert, CEO and Director, and David Schrader, COO of Scythian Biosciences Corp. (TSXV: SCYB) (“Scythian”) in an interview with InvestorIntel Senior Editor Peter Clausi discuss the cannabinoid drug Scythian has developed to treat traumatic brain injuries. David states the drug is for immediate use after impact “to try and prevent” continuing brain damage, tissue damage from inflammation and any additional damage from the body’s own immune response. Scythian has partnered with the “world renowned” University of Miami Medical Center, who will be completing the preclinical and clinical testing of Scythian’s cannabinoid drug.

Peter Clausi: Today we are discussing Scythian Biosciences Corp., a biotech company doing research in the cannabinoid space. Could you tell us something about the company?

David Schrader: This company started out in the medical marijuana field in Canada, and has a license application pending. About 2 years ago we changed into the drug development sector where we are focusing on drugs that are marijuana related, cannabinoids and we have one drug currently in testing at the University of Miami.

Peter Clausi: What drug are you testing?

David Schrader: We are testing a drug…It is a combination drug for traumatic brain injury. Whenever somebody gets a head injury, aside from the initial impact, there is a lot of tissue damage that happens after the actual injury.

Peter Clausi: This is what the NFL, CFL and the NHL have been addressing with their concussion protocols. Is that right?

David Schrader: It is, but a lot of the focus on the football arena really is the cumulative effect, CTE, that take place over a long period of time. Our drug is focused on immediately after an impact to try and prevent continuing brain damage that occurs, tissue damage from inflammation and from the body’s own immune response immediately after an injury.

Peter Clausi: You mentioned you are doing research with the University of Miami. Why Miami?

David Schrader: University of Miami Medical Center and the hospital have an amazing staff. They have a division that actually is world renowned, one of the top couple in the country that focuses on brain and spinal cord injuries. We have a team of some of the top doctors in the country who are specialists in different areas relating to brain injuries and spinal cord injuries… to access the complete interview, click here

Disclaimer: Scythian Bioscience Corp. is an advertorial member of InvestorIntel.


Kelly Bird

Editor:

Kelly Bird joined the InvestorIntel Corp. team as the Relationship Manager in 2016, and was quickly promoted to Creative Director. An interviewer, producer and video ... <Read more about Kelly Bird>


Copyright © 2017 InvestorIntel Corp. All rights reserved. More & Disclaimer »


Comments

  • Kelly Bird

    This is my favourite interview to date! Not sure if you saw their news release this AM…but they just applied for a listing on NASDAQ. Rocking it Scythian!

    August 30, 2017 - 9:25 AM

Leave a Reply

Your email address will not be published. Required fields are marked *